Pulmonary Arterial Hypertension
A progressive disease causing severe narrowing of the lung arteries, leading to high pressure in the lungs and ultimately right-sided heart failure.
Emergency Management: PAH crisis/Right Ventricular failure: Hypotension, tachycardia, and hypoperfusion. Requires admission to ICU, IV diuretics (Furosemide 40-80 mg IV), inhaled nitric oxide, and inotropes (Dobutamine or Milrinone) to support the right ventricle. Avoid intubation if possible as positive pressure ventilation severely decreases RV filling.
Pulmonary Arterial Hypertension is a rare, progressive vasculopathy characterized by elevated pulmonary artery pressure and vascular resistance in the absence of left heart disease or lung disease. It affects the precapillary pulmonary arterioles. The core pathology involves endothelial dysfunction, smooth muscle hypertrophy, and intimal proliferation, ultimately leading to right ventricular failure and death.
Detailed Overview
PAH is Group 1 of the WHO clinical classification of pulmonary hypertension. The remodeling of small pulmonary arteries causes a severe restriction in blood flow through the lungs. This increases right ventricular afterload, prompting compensatory right ventricular hypertrophy, which eventually fails, causing cor pulmonale. PAH is distinct from other forms of PH (like those secondary to COPD or left-sided heart failure) because it represents a primary intrinsic disease of the pulmonary vasculature. Without targeted vasodilatory and anti-proliferative therapy, median survival is under 3 years.
Epidemiology & Demographics
Incidence is 2-5 cases per 1 million adults per year. Prevalence is 15-50 cases per 1 million. Idiopathic PAH has a female predominance (ratio 3:1 to 4:1) with a mean age of diagnosis around 50 years, though heritable forms often present in the 30s.
Etiological Mechanism
Mutations in the BMPR2 gene account for ~75% of familial PAH cases and up to 25% of sporadic (idiopathic) cases. It can also be associated with connective tissue diseases (especially Systemic Sclerosis), HIV infection, portal hypertension, and exposure to certain drugs/toxins (e.g., aminorex, fenfluramines, methamphetamines).
Primary Causes
Idiopathic (IPAH), Heritable (BMPR2, ALK-1 mutations), Drug/Toxin-induced (anorexigens), Connective Tissue Diseases (Systemic Sclerosis, SLE), HIV infection, Portal Hypertension, Congenital Heart Disease (Eisenmenger syndrome), and Schistosomiasis.
Endothelial injury leads to an imbalance in vasoactive mediators: an overproduction of vasoconstrictors/mitogens (endothelin-1, thromboxane A2) and a deficiency of vasodilators/antiproliferative agents (nitric oxide, prostacyclin). This triggers pulmonary artery smooth muscle cell (PASMC) proliferation, endothelial cell apoptosis followed by hyperproliferation, and extracellular matrix deposition. These processes cause medial hypertrophy, intimal fibrosis, and the formation of plexiform lesions (complex vascular out-pouchings). The resultant narrowing increases pulmonary vascular resistance (PVR). The right ventricle (RV) initially hypertrophies to maintain cardiac output, but eventually dilates, leading to tricuspid regurgitation, reduced RV ejection fraction, and systemic venous congestion.
Diagnostic Criteria & Guidelines
Right Heart Catheterization (RHC) is the gold standard and required for diagnosis. Criteria: Mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest, Pulmonary Capillary Wedge Pressure (PCWP) <= 15 mmHg, and Pulmonary Vascular Resistance (PVR) >= 3 Wood Units. Vasoreactivity testing with inhaled nitric oxide is performed during RHC.
For WHO FC II-III: Initial combination therapy targeting two pathways. Endothelin receptor antagonist (e.g., Macitentan 10 mg PO daily or Ambrisentan 10 mg PO daily) PLUS a PDE5 inhibitor (e.g., Tadalafil 40 mg PO daily or Sildenafil 20 mg PO TID).
Second-Line & Adjunctive Therapy
For WHO FC IV or rapid progression: Addition of a prostacyclin analogue. Epoprostenol via continuous intravenous infusion (starting at 2 ng/kg/min and titrating up based on tolerance), or Treprostinil (IV/SC or inhaled).
Surgical & Procedural Management
Bilateral lung transplantation is the definitive treatment for severe, medically refractory PAH. Atrial septostomy may be performed as a palliative bridge to transplant to offload the failing right ventricle (creates right-to-left shunt, accepting hypoxia to improve cardiac output).
Patient Counseling & Advice
Pregnancy carries a 30-50% maternal mortality risk in PAH; strict contraception (progesterone-only or IUDs, avoiding estrogen) is absolutely mandatory. Inform patients about the complexity of managing IV prostacyclins if prescribed (risk of line infections, rebound severe PH if pump stops).
Follow-Up & Monitoring Schedule
Echocardiogram and NT-proBNP every 3-6 months. 6-Minute Walk Test (6MWT) at every clinic visit to assess functional capacity. Repeat Right Heart Catheterization if clinical status deteriorates.
Preventive Strategies
Screening high-risk populations (e.g., annual echocardiogram for patients with Systemic Sclerosis or known BMPR2 mutations) for early detection. No definitive prevention for idiopathic cases.
Despite modern combination therapy, PAH remains incurable. The 5-year survival rate is approximately 60-65%. Prognosis is significantly better for responders to calcium channel blockers (a very small subset) and worse for those associated with connective tissue diseases.